CANADA LIFE ASSURANCE Co decreased its position in DaVita Inc. (NYSE:DVA - Free Report) by 21.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 80,010 shares of the company's stock after selling 21,623 shares during the period. CANADA LIFE ASSURANCE Co owned 0.10% of DaVita worth $11,947,000 as of its most recent filing with the SEC.
Other hedge funds have also recently modified their holdings of the company. Invesco Ltd. raised its stake in shares of DaVita by 20.9% during the 4th quarter. Invesco Ltd. now owns 1,589,545 shares of the company's stock worth $237,716,000 after purchasing an additional 275,284 shares during the period. Amundi raised its holdings in shares of DaVita by 116.4% in the 4th quarter. Amundi now owns 446,386 shares of the company's stock worth $68,726,000 after purchasing an additional 240,126 shares during the period. Bridgewater Associates LP grew its holdings in DaVita by 298.4% during the fourth quarter. Bridgewater Associates LP now owns 239,970 shares of the company's stock valued at $35,888,000 after purchasing an additional 179,744 shares during the period. Skandinaviska Enskilda Banken AB publ raised its stake in shares of DaVita by 256.8% in the fourth quarter. Skandinaviska Enskilda Banken AB publ now owns 162,233 shares of the company's stock valued at $24,301,000 after buying an additional 116,758 shares during the period. Finally, JPMorgan Chase & Co. grew its stake in shares of DaVita by 17.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company's stock worth $99,846,000 after acquiring an additional 92,014 shares during the period. Institutional investors own 90.12% of the company's stock.
DaVita Price Performance
Shares of DVA stock traded up $0.01 during trading on Friday, hitting $139.57. The company had a trading volume of 600,714 shares, compared to its average volume of 841,722. The stock's 50-day moving average is $146.50 and its two-hundred day moving average is $155.24. The stock has a market capitalization of $11.17 billion, a price-to-earnings ratio of 13.00, a price-to-earnings-growth ratio of 1.07 and a beta of 1.04. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18. DaVita Inc. has a 52 week low of $131.27 and a 52 week high of $179.60.
DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The company reported $2.24 EPS for the quarter, topping analysts' consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. As a group, analysts predict that DaVita Inc. will post 10.76 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several equities research analysts have commented on the stock. StockNews.com raised shares of DaVita from a "hold" rating to a "buy" rating in a report on Friday. Cowen reissued a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. Barclays boosted their price objective on DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research note on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 price target on shares of DaVita in a report on Friday, February 21st. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, DaVita presently has an average rating of "Hold" and an average price target of $166.33.
Get Our Latest Stock Report on DVA
About DaVita
(
Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Articles
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
